NCT02160158 - Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Healthy

Interventions

DRUG

Fesoterodine ER (fasted)

Commercial Fesoterodine ER 4 mg (single dose)

DRUG

Fesoterodine SR3 (fasted)

Fesoterodine SR3 4 mg (single dose)

DRUG

Fesoterodine SR3 (fed)

Fesoterodine SR3 4 mg (single dose) with high-fat meal

DRUG

Fesoterodine ER (fed)

Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal

DRUG

Fesoterodine SR3 (sprinkle)

Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce

DRUG

Fesoterodine ER (fasted)

Commercial Fesoterodine ER 4 mg (single dose)

DRUG

Fesoterodine SR4 (fasted)

Fesoterodine SR4 4 mg (single dose)

DRUG

Fesoterodine SR4 (fed)

Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal

DRUG

Fesoterodine ER (fed)

Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal

DRUG

Fesoterodine SR4 (sprinkle)

Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels